Decitabine

Name: Decitabine
Brand: Selleck Chemicals
SKU: S1200
Rating: 5 (69 reviews)

For research use only.

Catalog No.S1200 Synonyms: Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine

69 publications

Molecular Weight(MW): 228.21

Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.

Selleck's Decitabine has been cited by 69 publications

Nat Biotechnol, 2019, 10.1038/s41587-019-0372-z

PubMed: 31873215 ( click the link to review the publication )

Nat Med, 2019, 25(7):1073-1081

PubMed: 31270502 ( click the link to review the publication )

Cancer Discov, 2019, 9(1):34-45

PubMed: 30297358 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell Metab, 2019, 29(4):886-900

PubMed: 30661930 ( click the link to review the publication )

Cancer Cell, 2018, 34(6):906-921

PubMed: 30537513 ( click the link to review the publication )

Nat Commun, 2020, 6;11(1):740

PubMed: 32029739 ( click the link to review the publication )

Oncogene, 2020, 11

PubMed: 32393833 ( click the link to review the publication )

J Cancer, 2020, 28;11(10):2874-2886

PubMed: 32226505 ( click the link to review the publication )

Oncogenesis, 2020, 13;9(5):48

PubMed: 32404892 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(9):5260-5273

PubMed: 32227582 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Int J Oncol, 2020, 56(6):1429-1441

PubMed: 32236593 ( click the link to review the publication )

Clin Sci (Lond), 2020, 134(2):273-287

PubMed: 31957803 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(13):4155-4167

PubMed: 30952643 ( click the link to review the publication )

Theranostics, 2019, 9(9):2424-2438

PubMed: 31131045 ( click the link to review the publication )

Theranostics, 2019, 9(21):6175-6190

PubMed: 31534544 ( click the link to review the publication )

Cancer Res, 2019, 79(10):2761-2774

PubMed: 30877105 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Cell Death Differ, 2019, 26(5):843-859

PubMed: 29988076 ( click the link to review the publication )

J Nucl Med, 2019, 10.2967/jnumed.118.224048

PubMed: 30796167 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12849

PubMed: 31758842 ( click the link to review the publication )

Signal Transduct Target Ther, 2019, 4:51

PubMed: 31815008 ( click the link to review the publication )
ACS Chem Biol, 2019, 14(3):348-355

PubMed: 30763062 ( click the link to review the publication )

Mol Pharm, 2019, 16(5):1813-1826

PubMed: 30883132 ( click the link to review the publication )

J Cell Physiol, 2019, 234(8):14040-14049

PubMed: 30623427 ( click the link to review the publication )

Eur J Nutr, 2019, 10.1007/s00394-019-01925-6

PubMed: 30762097 ( click the link to review the publication )

Biomed Pharmacother, 2019, 112:108699

PubMed: 30970511 ( click the link to review the publication )

Front Genet, 2019, 10:422

PubMed: 31130994 ( click the link to review the publication )

Life Sci, 2019, 218:241-252

PubMed: 30586565 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):202

PubMed: 30841886 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 10.1016/j.bbrc.2019.06.097

PubMed: 31277942 ( click the link to review the publication )

Mol Biol Rep, 2019, 10.1007/s11033-019-04892-7

PubMed: 31147860 ( click the link to review the publication )

Sci Rep, 2019, 9(1):16970

PubMed: 31740746 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):446-462

PubMed: 29202477 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3164

PubMed: 30089774 ( click the link to review the publication )

Nat Commun, 2018, 13;9(1):2720

PubMed: 30006524 ( click the link to review the publication )

Leukemia, 2018, 32(4):900-910

PubMed: 29249821 ( click the link to review the publication )

Theranostics, 2018, 8(16):4520-4534

PubMed: 30214636 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):62

PubMed: 29728108 ( click the link to review the publication )

Oncoimmunology, 2018, 7(10):e1484981

PubMed: 30288346 ( click the link to review the publication )

J Gastroenterol, 2018, 53(1):71-83

PubMed: 28315004 ( click the link to review the publication )

Oncogenesis, 2018, 7(11):91

PubMed: 30467308 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):696-706

PubMed: 29453320 ( click the link to review the publication )

Antimicrob Agents Chemother, 2018, 62(9)

PubMed: 29914957 ( click the link to review the publication )

Cancer Immunol Immunother, 2018, 67(2):237-246

PubMed: 29058035 ( click the link to review the publication )

Biomed Pharmacother, 2018, 104:204-210

PubMed: 29772441 ( click the link to review the publication )
Leuk Res, 2018, 64:34-41

PubMed: 29175379 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2304-2314

PubMed: 28729399 ( click the link to review the publication )

Br J Haematol, 2017, 10.1111/bjh.14707

PubMed: 28439875 ( click the link to review the publication )

J Biol Chem, 2017, 292(31):12842-12859

PubMed: 28634230 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2017, 143(11):2189-2200

PubMed: 28730284 ( click the link to review the publication )

Am J Transl Res, 2017, 9(2):454-465

PubMed: 28337274 ( click the link to review the publication )

Alcohol, 2017, 60:95-101

PubMed: 28433417 ( click the link to review the publication )

Oncotarget, 2017, 8(34):56802-56815

PubMed: 28915632 ( click the link to review the publication )

Oncotarget, 2017, 8(51):89182-89193

PubMed: 29179510 ( click the link to review the publication )

Nat Commun, 2016, 7:11040

PubMed: 27010513 ( click the link to review the publication )

Mol Cell Biochem, 2016, 415(1-2):197-205

PubMed: 27000860 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(7):1628-38

PubMed: 25623213 ( click the link to review the publication )

Cancer Res, 2015, 75(15):2987-98

PubMed: 26122843 ( click the link to review the publication )

J Immunol, 2015, 10.4049/jimmunol.1403196

PubMed: 25825452 ( click the link to review the publication )

Cell Cycle, 2015, 10.1080/15384101.2015.1044174

PubMed: 25946202 ( click the link to review the publication )

Oncol Lett, 2015, 9(4):1691-1698

PubMed: 25789025 ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(9):1030-41

PubMed: 26056145 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(22):4143-64

PubMed: 25202123 ( click the link to review the publication )

PLoS One, 2014, 9(5):e97719

PubMed: 24874286 ( click the link to review the publication )

Exp Hematol, 2014, 42(7):536-46

PubMed: 24704162 ( click the link to review the publication )

Leuk Res, 2014, 38(3):402-10

PubMed: 24484870 ( click the link to review the publication )

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description

Targets

DNA methylation ^[1]
(HL-60, KG1a cells)

In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. ^[1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [³H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Eca109	NHzrR5BHfW6ldHnvckBCe3OjeR?=	MmTSNE42yqEQvF2=	MUmyOEBp	MVX3ZZRmeg>?	Ml\JcY9lfWyjdHXzJJRp\SCpZX7lJIV5eHKnc4Ppc44hd2ZiTVHHSU1CKG2nbXLldpM>	MVKyOVEzOzB6Mh?=
Eca109	NHz1d4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HEUVAvPS9{LkWvOUDPxE1?	M1yxS\|I1NzR6L{eyJIg>	NYKwS\|RNf2G2ZYK=	MY\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJIRwe2VvIHHu[EB1cW2nLTDk[ZBmdmSnboSgcYFvdmW{	NXL3SFRFOjVzMkOwPFI>
Eca109	NWHwVmQ6TnWwY4Tpc44hSXO\|YYm=	MorPNE42yqEQvF2=	MYW2M\|EzNzJ2IHi=	MUX3ZZRmeg>?	M1HzUYlvcGmkaYTzJINmdGxibXnndoF1cW:wwrC=	NFnrRVAzPTF{M{C4Ni=>
Eca109	M{[2eWZ2dmO2aX;uJGF{e2G7	NX;td3VbOC53wrFOwG0>	M17mblI1KGh?	MWr3ZZRmeg>?	NV[zTVg3cW6qaXLpeJMh[2WubDDpcpZie2mxbh?=	MV2yOVEzOzB6Mh?=
Eca109	NWfZOpZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2CwUVAvPcLizszN	M3ewe\|I1KGh?	NYD0Om9Uf2G2ZYK=	NEDIeWVqdmS3Y3XzJGczN01iYYLy[ZN1KGmwIITo[UBk\WyuIHP5Z4xm	NXH5NGtZOjVzMkOwPFI>
Eca109	MYfGeY5kfGmxbjDBd5NigQ>?	MYCwMlUwOSEQvF2=	NGfnWGIzPCCq	NUDrO41wf2G2ZYK=	M{XoeIRm[3KnYYPld{BmgHC{ZYPzbY9vKG:oIF7GMe67SjJiYX7kJG1OWDJ?	NHy5TIUzPTF{M{C4Ni=>
SW1116	M336SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnvxNE42NzFxMj:1JO69VQ>?	Ml6wOFghcA>?	M1:1fGROW09?	M2[4eoVvcGGwY3XzJJRp\SCJZX\peIlvcWJiaX7keYNm\CClZXzsJIlvcGmkaYTpc44>	NUXoNINEOjR6N{SyPFY>
LOVO	MknzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPnPG0xNjVxMT:yM\|Uh\|ryP	MUe0PEBp	M2XoRWROW09?	NF7tNphmdmijbnPld{B1cGViR3XmbZRqdmmkIHnu[JVk\WRiY3XscEBqdmirYnn0bY9v	NI\oe5QzPDh5NEK4Oi=>
SW1116	M2GzVWZ2dmO2aX;uJGF{e2G7	M3TnN\|ExKM7:TR?=	M33WUVQ5KGh?	NH\COI5FVVOR	NYriTY9ScW6lcnXhd4V{KHSqZTDl[oZm[3SrdnWgZZQhcW6qaXLpeIlv\yCDS2SgZY5lKG2WT2Kgd4lodmGuaX7nJJBifGi5YYnzJINwdWKrbnXkJJdqfGhiZ3XmbZRqdmmk	MkLMNlQ5PzR{OE[=
LOVO	MmLRSpVv[3Srb36gRZN{[Xl?	MlnONVAh\|ryP	NH3UWZM1QCCq	NGSzWFZFVVOR	MXLpcoNz\WG\|ZYOgeIhmKGWoZnXjeIl3\SCjdDDpcohq[mm2aX7nJGFMXCCjbnSgcXRQWiC\|aXfuZYxqdmdicHH0bJdigXNiY3;tZolv\WRid3n0bEBo\W[rdHnubYI>	NHu5UIUzPDh5NEK4Oi=>
SW1116	Ml\SRZBweHSxc3nzJGF{e2G7	MWKxNEDPxE1?	Ml\GOFghcA>?	NIPhVVFFVVOR	Mnfj[Y5p[W6lZYOgS4VncXSrbnniMYlv\HWlZXSgZZBweHSxc3nz	MmThNlQ5PzR{OE[=
LOVO	NU\Ge\|VOSXCxcITvd4l{KEG\|c3H5	M2\YdVExKM7:TR?=	M1LIWVQ5KGh?	Ml7pSG1UVw>?	NUDBZ4Zs\W6qYX7j[ZMhT2WoaYTpcoljNWmwZIXj[YQh[XCxcITvd4l{	MnTRNlQ5PzR{OE[=
RPMI-8226	MmnWRZBweHSxc3nzJGF{e2G7	NIr0RnQyNzJizszN	MWW0PE84Oi97NjDo	Ml;tSG1UVw>?	MkXlbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	NFrIVFczPDh\|M{GwPC=>
OPM-2	MXrBdI9xfG:\|aYOgRZN{[Xl?	NGjKOooyNzJizszN	NYHPbpRJPzJxOU[vNVIxKGh?	MV7EUXNQ	NWG3S\|hGcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	NHfVTHEzPDh\|M{GwPC=>
JJN3	NWXLc3NQSXCxcITvd4l{KEG\|c3H5	MmTINE42NzFizszN	NYLUXIFJOjRxNEigbC=>	MkSzSG1UVw>?	NHL1OmlqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	M{jaSlI1QDN\|MUC4
NCI-H929	NUmyXJJmSXCxcITvd4l{KEG\|c3H5	MniwNU8zKM7:TR?=	NXXBdJh6PzJxOU[vNVIxKGh?	MoPISG1UVw>?	M17mbIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	NX[zcoxMOjR6M{OxNFg>
RPMI-8226	NX\TWFVIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3VNU8zKM7:TR?=	MojrNlQwPDhxN{KgbC=>	M4O1N2ROW09?	MX;h[oZm[3S\|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>?	Mn3rNlQ5OzNzMEi=
OPM-2	MoLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF3ne4QyNzJizszN	NGrySIUzPC92OD:3NkBp	NYnTd3p6TE2VTx?=	NFvRW5Zi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?=	MnywNlQ5OzNzMEi=
JJN3	NWjCUFFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37DU\|AvPS9zIN88US=>	NYS0O4VDOjRxNEivO\|IhcA>?	NF3KNmNFVVOR	M{HCeoFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7	MVyyOFg{OzFyOB?=
NCI-H929	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nk[\|EwOiEQvF2=	MoXxNlQwPDhxN{KgbC=>	M3q4NmROW09?	M3zEeYFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7	NF3RPIMzPDh\|M{GwPC=>
HeLa	M3j0TGtqdmG\|ZTDBd5NigQ>?				NWPBVZp2U2l;MUCwNQKBmzVyMECg{txOKG[xcjDoSW5VOQ>?	NIDKbJYzPDd6MEC5PC=>
HeLa	M3rxSGtqdmG\|ZTDBd5NigQ>?				MoDDT4k:PS54INMxJFAvPSEQvF2g[o9zKGiHTmSy	MkXwNlQ4QDByOUi=
HeLa	NX;Z[455U2mwYYPlJGF{e2G7				NH3Td25McT1{MT62JOKyKDNwMDFOwG0h\m:{IHjDUnQy	NXey[m1OOjR5OECwPVg>
HeLa	NYmyZWY2U2mwYYPlJGF{e2G7				M2HB[WtqRTF2LkSgxtEhPC54IN88UUBnd3JiaFPOWFM>	NGnPTGIzPDd6MEC5PC=>
NB4	NFXK[XBHfW6ldHnvckBCe3OjeR?=	M3vpSlIvPS93L{euOU8yOCEQvF2=	M3rJdlI1KGh?	M3f2OWROW09?	MUjpcoNz\WG\|ZXGgeIhmKGW6cILld5Nqd25ib3[gdJJm[3W{c3;yJI1qWi1zMkXh	NFH0ZYEzPDR6NEi3NC=>
CD4+ CD25− T	MnrzSpVv[3Srb36gRZN{[Xl?	M1P1VlEwPSEQvF2=			M1v4[JJm\HWlZWOg[4xw[mGuIFTORUBu\XSqeXzheIlwdg>?	MoH5NlQ1PzZ\|NkC=
BV-173	MnXkRZBweHSxc3nzJGF{e2G7	MXqwMlI2NzBwNT:wMlc2NzFizszN	MonuOFgwPzJxOU[gbC=>	NYr2XodEyqCSQmO=	MmPIbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy	MW[yOFQzOzZzMx?=
ML-1	M3zMZ2Fxd3C2b4Ppd{BCe3OjeR?=	M1HHZlAvOjVxMD61M\|AvPzVxMTFOwG0>	M4HsZVQ5Nzd{L{m2JIg>	NFv5WW7DqFCEUx?=	MoG4bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy	NHzi[JczPDR{M{[xNy=>
HL-60	NFLGOoRCeG:ydH;zbZMhSXO\|YYm=	MlXoNE4zPS9yLkWvNE44PS9zIN88US=>	M{HiZVQ5Nzd{L{m2JIg>	MliyxsBRSlN?	NUOzXHBbcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz	M{j2e\|I1PDJ\|NkGz
KG-1a	NUTxTGpRSXCxcITvd4l{KEG\|c3H5	MlG3NE4zPS9yLkWvNE44PS9zIN88US=>	M3;OU\|Q5Nzd{L{m2JIg>	MV1CpHBDWw>?	M1vmZ4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=>	M4jPRlI1PDJ\|NkGz
BV-173	NInxSZdHfW6ldHnvckBCe3OjeR?=	MlSyNlUxNzVyMH7N	MXW0PEBp	NWfKVJVoyqCSQmO=	NYq1W5R7cW6mdXPld{Bl\WyjeXXkJIFv\CC\|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl	M{nD[FI1PDJ\|NkGz
CEM	MVnGeY5kfGmxbjDBd5NigQ>?	NEjzOpAzPTBxNUCwcm0>	NXrrc\|BtPDhiaB?=	NH7RfJXDqFCEUx?=	MY\pcoR2[2W\|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V?	NGX2bZQzPDR{M{[xNy=>
HL-60	NXK2eZpwTnWwY4Tpc44hSXO\|YYm=	MXmyOVAwPTBybl2=	NYnhTJZoPDhiaB?=	M1y3b:KhWEKV	MWrpcoR2[2W\|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V?	MVOyOFQzOzZzMx?=
ML-1	NVHGRmUzTnWwY4Tpc44hSXO\|YYm=	NIewPGUzPTBxNUCwcm0>	M13HTlQ5KGh?	MWJCpHBDWw>?	NFPKcGRqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W=	M3LmTlI1PDJ\|NkGz
DLD-1	NGTCRYZHfW6ldHnvckBCe3OjeR?=	Ml;aNlUxNzVyMH7N	MWS0PEBp	NGHINYHDqFCEUx?=	NW\nV4E4\G9ibn;0JIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W\|dHHpcoVlKFKRUzDpcoNz\WG\|ZR?=	MViyOFQzOzZzMx?=
HCT-116	NEnEeFNHfW6ldHnvckBCe3OjeR?=	M1jjWFI2OC93MEDuUS=>	NGnh[Xc1QCCq	NXjZN\|RzyqCSQmO=	M1vmPIRwKG6xdDDpcoR2[2W\|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V?	MoXHNlQ1OjN4MUO=
U937-A/E-9/14/18	NXP2NY91SXCxcITvd4l{KEG\|c3H5	Ml3BNE4xOS9yLkGvNU8yOCEQvF2=	NIm2NVA1QCCq		NXv4VIxKcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NETwd\|AzPDNyMES1Oi=>
HT29	Mo\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlLTO\|IhcA>?		MkHsTWM2OD1zNECwxtEyPzlizszN	Ml7KNlQyPzJyNkG=
SW48	Mnj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1v0NlczKGh?		MlfuTWM2OD1zNT6yxtE3NjJizszN	NYW0RlRKOjRzN{KwOlE>
HCT116	NGDNdVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3XCcFczKGh?		NVTHbpE{UUN3ME2xMlfDuTBwNDFOwG0>	M2DtWFI1OTd{ME[x
HepG2	NWLQbFc{TnWwY4Tpc44hSXO\|YYm=	MmjrNE42NzFizszN	M4ixS\|I1KGh?	MYLEUXNQ	NIPM[YN2eC2{ZXf1cIF1\WRidHjlJJJmdGG2aY\lJG9EXE5{IH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?=	NUjFfFlLOjRzNE[4O\|Q>
LS174T	M17Q[mZ2dmO2aX;uJGF{e2G7	M4K0c\|AvPS9zIN88US=>	NVTkR2U6OjRiaB?=	NF\HfmRFVVOR	NGj4SXJt\WGmIITvJIFvKGmwY4LlZZNmKG:oIF;DWG4zKGyndnXsdy=>	MU[yOFE1Pjh5NB?=
HepG2	M37jPGFxd3C2b4Ppd{BCe3OjeR?=	MlXoNU8yOC9zMECg{txO	NFv0NWo4KGR?	NFLIO45FVVOR	MX;pcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MVWyOFE1Pjh5NB?=
LS174T	Ml\JRZBweHSxc3nzJGF{e2G7	M2TpelEwOTBxMUCwJO69VQ>?	M4fJNVch\A>?	M3;W[mROW09?	MUTpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MVeyOFE1Pjh5NB?=
QBC-939	MWDBdI9xfG:\|aYOgRZN{[Xl?	MXSxM\|ExNzFyMDFOwG0>	M4jKTFch\A>?	M13tfWROW09?	NF3PbYJqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MYqyOFE1Pjh5NB?=
U251	MYLBdI9xfG:\|aYOgRZN{[Xl?	NGn1U\|IyNzFyL{GwNEDPxE1?	MV63JIQ>	MlLmSG1UVw>?	NVO0cINpcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	M4izXFI1OTR4OEe0
HL-60	MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnkeY14OSEQvF2=	Mn2yOFghcA>?		MWrpcoNz\WG\|ZYOgS\|IueGijc3WgZ4VtdCCocnHjeIlwdg>?	NUfidJBJOjRyMECzNlQ>
MDA‑MB‑453	NVPCRXdVTnWwY4Tpc44hSXO\|YYm=	M1;leVAvOi9zIN88US=>	NXPZeo1YPzJiaB?=		MW\jZZV{\XNicnWt[ZhxemW\|c3nvckBw\iClbHH1[IlvyqBzwrC=	Mm\lNlM5PDR{Mki=
HCC1569	NWnGeYxuTnWwY4Tpc44hSXO\|YYm=	M3vCWVAvOi9zIN88US=>	MXW3NkBp		MVfjZZV{\XNicnWt[ZhxemW\|c3nvckBw\iClbHH1[IlvyqBzwrC=	NIDhV\|QzOzh2NEKyPC=>
BT‑474	NFTofnhHfW6ldHnvckBCe3OjeR?=	NEjkOJMxNjJxMTFOwG0>	NITWU3E4OiCq		NHL1NVNk[XW\|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA>	M1PiTlI{QDR2MkK4
AGS	NF3TW3JCeG:ydH;zbZMhSXO\|YYm=	MmixOU8yOC9{MD:1NEDPxE1?	M2PnWFQ5yqCqwrC=	MV7EUXNQ	NEfubppqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJnDqA>?	NFTrdWkzOzV6Mke4OC=>
A549	MX7BdI9xfG:\|aYOgRZN{[Xl?	M2DvVlUwOTBxMkCvOVAh\|ryP	NGH2[5k1QMLiaNMg	NWDhbY06TE2VTx?=	NULmOVdvcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6yqB?	NVLkOGZCOjN3OEK3PFQ>
AGS	NXnhdnJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\NOU8yOC9{MD:1NEDPxE1?	M1zE[FQ5yqCqwrC=	M{DPV2ROW09?	NUO1XmJzcW6mdXPld{BIOi:PIIDoZZNmKGG{cnXzeOKh	NVOwZ\|E5OjN3OEK3PFQ>
Kasumi-1	MVnBdI9xfG:\|aYOgRZN{[Xl?	MkHqNE42KM7:TR?=	M3zwdFQ5yqCqwrC=		NXL4bIs6\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M>	NUnYbIpKOjN2OUOzOFg>
OCI-AML3	NH;MSmxCeG:ydH;zbZMhSXO\|YYm=	NILFNWIzNjVizszN	NEGwNIE1QMLiaNMg		NUfGN29V\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M>	MmnaNlM1QTN\|NEi=
MV4-11	NFzLUJZCeG:ydH;zbZMhSXO\|YYm=	M2jndlIvPSEQvF2=	M3XBWlQ5yqCqwrC=		M2HFeIRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj	MVmyN\|Q6OzN2OB?=
NK	M2HtTmN6fG:2b4jpeJkhSXO\|YYm=	M3rwSVAvODJvMkCg{txO	MXy1JIQ>		NGm2W3Jl\WO{ZXHz[ZMhfGinIHP5eI9tgXSrYzDhZ5Rqfmm2eTDv[kBPUyClZXzsd{BifCCrboTldo1m\GmjdHWgZ49v[2WwdILheIlwdnNicnXzeYx1cW6pIHnuJIEhXS2\|aHHw[YQh\G:\|ZfMAl5Jme3CxboPlJIN2en[n	M3ntdFI{OzJ6MEi4
NK	M4rn[WFxd3C2b4Ppd{BCe3OjeR?=	NIHKTmkxNjB{LUKwJO69VQ>?	NUDsTpdzPSCm		MWfk[YNz\WG\|ZTDOT{Bk\WyuIIDyc4xq\mW{YYTpc44h[W6mII\pZYJqdGm2eTDhd{B1cGViY3;uZ4VvfHKjdHnvckBqdmO{ZXHz[YQ>	MoDiNlM{OjhyOEi=
NK	Ml:2SpVv[3Srb36gRZN{[Xl?	MXSwMlAyNTJyIN88US=>	MkLqOUBl		Mn7TZ4F2e2W\|IHj5dI9u\XSqeXzheIlwdiCxZjDOT{Bk\WyuczDpckBiKGSxc3ZihLNz\XOyb37z[S=>	MoDrNlM{OjhyOEi=
MOLT4/DNR	NHzlSHlHfW6ldHnvckBCe3OjeR?=	M2rjPVUh\|ryP	MnjQOEBl		M{LwU5Jm\HWlZYOgRWJESjFibWLORUBmgHC{ZYPzbY9v	MXiyN\|A3ODV5MB?=
Jurkat/DOX	MofvSpVv[3Srb36gRZN{[Xl?	Mn[yOUDPxE1?	NVO3eVhxPCCm		MkPndoVlfWOnczDBRmNDOSCvUl7BJIV5eHKnc4Ppc44>	M3TLfVI{ODZyNUew
MOLT4/DNR	NIfmRpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUK1JO69VQ>?	MXK0JIQ>		MkTRdoVlfWOnczD0bIUhUUN3MNMgeoFtfWViZn;yJIRifW6xcoXibYNqdiC\|ZX7zbZRqfmm2eR?=	NVvueJVZOjNyNkC1O\|A>
Jurkat/DOX	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLzOUDPxE1?	MkLNOEBl		MUDy[YR2[2W\|IITo[UBKSzVywrD2ZYx2\SCob4Kg[IF2dm:{dXLpZ4lvKHOnboPpeIl3cXS7	NFfvV\|MzOzB4MEW3NC=>
ccRCC	NWfofXNVSXCxcITvd4l{KEG\|c3H5	MnHsNE4xOS1zMN88US=>	MnXPO\|IhcA>?	NVnad4FuTE2VTx?=	MVjoZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v	MXyyNlgzPjR4Nx?=
TNBC	MoOzRZBweHSxc3nzJGF{e2G7	M1nWUlAvODFvMUFOwG0>	NInSVIw4OiCq	MYrEUXNQ	NIHN[pRp[XNibXnubY1idCCnZn\lZ5Qhd25iY3XscEBxem:uaX\ldoF1cW:w	MWCyNlgzPjR4Nx?=
A498	MWHBdI9xfG:\|aYOgRZN{[Xl?	M4ezVlAvODFvMUFOwG0>	NWnj[nRtPzJiaB?=	MWjEUXNQ	NIDJXJNqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv	Mln0NlI5OjZ2Nke=
KIJ265T	NFrveo5CeG:ydH;zbZMhSXO\|YYm=	M2\LZlAvODFvMUFOwG0>	NFuxPVY4OiCq	MYTEUXNQ	Mn3GbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=>	NU\D[JROOjJ6Mk[0Olc>
MDA-231	NE\yNmxCeG:ydH;zbZMhSXO\|YYm=	NUi5XFZROC5yMT2xNO69VQ>?	NIjnZ3g4OiCq	NH[wSGJFVVOR	MXXpcoR2[2W\|IIP5coVz\2m\|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu	MkjnNlI5OjZ2Nke=
BT-20	NHW4RVdCeG:ydH;zbZMhSXO\|YYm=	MmXVNE4xOS1zMN88US=>	NWDs[3pmPzJiaB?=	MVHEUXNQ	NIT4TmdqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv	M2fIUVIzQDJ4NE[3
U937	MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2q4[lUuOjBizszN	Mn3pNlQwPDhxN{KgbC=>		MWnpcoR2[2W\|IHGg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy	NHvQdHIzOjd4N{CyNS=>
HL60	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TTSVUuOjBizszN	M2nCU\|I1NzR6L{eyJIg>		NVfLZWRDcW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>?	M2TFUVIzPzZ5MEKx
U937	M4\LbWFxd3C2b4Ppd{BCe3OjeR?=	MX6xOUDPxE1?	Mk\5NlQwPDhxN{KgbC=>		MYnpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	M4fKW\|IzPzZ5MEKx
HL60	M2qwNmFxd3C2b4Ppd{BCe3OjeR?=	MXyxOUDPxE1?	NFi3[JQzPC92OD:3NkBp		MXnpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	NX\6O5VHOjJ5NkewNlE>
LS411N	MlrHRZBweHSxc3nzJGF{e2G7	NVflOJFvOC53IN88US=>	NUGyW2JXPzJiaB?=		M3\CS4lv[3KnYYPld{BH[XNibWLORUBt\X[nbB?=	M17DWFIzPDZzNkm1
MDA-MB-231	MkDjRZBweHSxc3nzJGF{e2G7	MV6xNEDPxE1?	M13sRVQ5KGh?		Mon3doVlfWOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	M3vIfVIyQDh5Nkm3
MCF-7	M2D2TmFxd3C2b4Ppd{BCe3OjeR?=	NGrueXUyOCEQvF2=	M2PMWVQ5KGh?		NULufnVuemWmdXPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NVfQd5EyOjF6OEe2PVc>
A375	NWf2T5ViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoruNE42KM7:TR?=	Ml3PNU82NzhiZB?=		NG\HNpZqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?=	NHPvU2czOTd7Nk[yNi=>
SKMEL1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPDfWc3OC53IN88US=>	MknxNU82NzhiZB?=		MVTpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W\|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>?	MW[yNVc6PjZ{Mh?=
SKMEL3	NEHJXYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXOwMlUh\|ryP	NID6dFMyNzVxODDk		MU\pcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W\|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>?	NGH0eYIzOTd7Nk[yNi=>
SKMEL28	NH3XSHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPJSY84OC53IN88US=>	MX6xM\|UwQCCm		NV\LZYpicW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO=	NXm0b\|lYOjF5OU[2NlI>
MeWo	NIjrbotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTXNE42KM7:TR?=	Mo\xNU82NzhiZB?=		NXHsSW1jcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO=	M{\DSFIyPzl4NkKy
B16	NUnrNZFIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHkNE42KM7:TR?=	MWSxM\|UwQCCm		M{Xr[IlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy\|	NVrmVJhNOjF5OU[2NlI>
Ly 1	M2PoN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXzsOJc4OjRiaB?=		NUPwU5M{UUN3ME23MlMh\|ryP	MlXHNlE4PzJyNEm=
Ly 7	MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVrqcWJ{OjRiaB?=		NVfiVINWUUN3ME2xNE44KM7:TR?=	NFzxOpEzOTd5MkC0PS=>
Su-DHL6	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1:4TVI1KGh?		Mo\mTWM2OO,:nkKwJO69VQ>?	NGPTNpIzOTd5MkC0PS=>
Ly 10	NFLD[3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXHocWl3OjRiaB?=		MmjxTWM2OO,:nkKwJO69VQ>?	NEDPUoUzOTd5MkC0PS=>
RIVA	NIH3WHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVPJeWtbOjRiaB?=		NVXpXJo4UUN3MP-8olIxKM7:TR?=	MkHjNlE4PzJyNEm=
Su-DHL2	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MV6yOEBp		NH\LZZRKSzVy78{eNlAh\|ryP	NUO0U2R4OjF5N{KwOFk>
Ly 1	NIfsU21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1XvOFQ5KGh?		NUC4fIpuUUN3ME2wMlM1KM7:TR?=	MXeyNVc4OjB2OR?=
Ly 7	M3z0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2qyNlQ5KGh?		NI\6bnBKSzVyPUCuNFI2KM7:TR?=	M{DGcFIyPzd{MES5
Su-DHL6	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkD4OFghcA>?		NHHiSGJKSzVy78{eNlAh\|ryP	NFr0RoozOTd5MkC0PS=>
Ly 10	M17GUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{LGdVQ5KGh?		NVr1TY04UUN3ME2xMlgh\|ryP	MXKyNVc4OjB2OR?=
RIVA	NHPSNJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYC0WVloPDhiaB?=		MlztTWM2OO,:nkKwJO69VQ>?	MnrWNlE4PzJyNEm=
Su-DHL2	NGjoU2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIT5TYw1QCCq		M2i5dWlEPTB;MUeuOEDPxE1?	MY[yNVc4OjB2OR?=
Ly 1	M3fxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFe0TGM4OiCq		NWTDZmNUUUN3ME2wMlAyKM7:TR?=	MXGyNVc4OjB2OR?=
Ly 7	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{\vXFczKGh?		Mn[wTWM2OD1yLkCxPEDPxE1?	MkDNNlE4PzJyNEm=
Su-DHL6	NEnVdVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFj5c3I4OiCq		MYrJR\|UxRTFwNjFOwG0>	MlqxNlE4PzJyNEm=
Ly 10	NFPVXZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkO1O\|IhcA>?		NF3w[nBKSzVyPUGuNkDPxE1?	MlXLNlE4PzJyNEm=
RIVA	M37iRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mn7nO\|IhcA>?		MUXJR\|Ux97zgMkCg{txO	MX2yNVc4OjB2OR?=
Su-DHL2	MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NILuOXo4OiCq		M1LvfmlEPTB;MUGuNkDPxE1?	Ml[2NlE4PzJyNEm=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Survivin / Bcl-2 / p53 / c-Myc / DNMT1; PubMed: 26384351 Oncotarget HL60/ADR and kasumi-1 cells were lysed after treated with 0, 1, 2, 4μM decitabine for 72h, and antibodies against β-actin was used as loading control of whole cell proteins in western blotting. The expression of DNMT1, c-Myc, P53, Bcl-2 and Survivin were determined in AML cells. p-AKT / AKT / p-GSK3β / GSK3β / p-Myc / Myc / p-P70 / P70 / p-4EBP-1 / 4EBP-1 / PTEN; PubMed: 25762617 Oncotarget Effects of decitabine on the expression of survival pathway proteins at the indicated concentrations. phospho-p38 / p38 / phospho-NFκB / NFκB; PubMed: 26617834 Int J Clin Exp Pathol Decitabine suppressed the phosphorylation of p38 and NF-κB. p-JAK1 / JAK1 / p-JAK2 / JAK2 / p-STAT3 / STAT3 ; PubMed: 26692933 Am J Transl Res DAC inhibits the activity of JAK/STAT3 signaling pathway in HL-60 cells. A. HL-60 cells were exposed to 0.2-1.0 μM DAC for 48 h. Cell lysates were prepared and subjected to western blot assay for p-STAT3 (Tyr705 and Ser727) and total STAT3 protein. DAC treatment led to the dephosphorylation of STAT3 both at Tyr705 and Ser727, with moderate effect on total STAT3 protein. B. DAC also down-regulated the expression of p-JAK1 and p-JAK2 as well as total JAK1 and JAK2 in HL-60 cells. The protein expression of STAT3 and JAKs was normalized to that of β-actin and results are representative from three independent experiments. E-cadherin / N-cadherin / Snail / MMP-2 / MMP-9 / Bcl-2 / Bax; PubMed: 28152502 Oncotarget The protein level of EMT and invasion related proteins E-cadherin, N-cadherin, Snail, MMP-2, MMP-9 and the protein level of the apoptotic-related proteins, BCL-2 and Bax were detected by western blot. β-actin served as a internal control.	26384351 25762617 26617834 26692933 28152502
Immunofluorescence	DNMT1; PubMed: 21303982 Cancer Res Ren-01 cells (low passage number RCC cells) at <40% confluence were treated with decitabine 0.5 μM. DNMT1 was quantified 48 hours later by immuno-fluorescence (green dots). DAPI was used to stain nuclei (blue stain). E-cadherin / MMP-9; PubMed: 28152502 Oncotarget Immunofluorescence microscopy to identify invasion-promoting molecule MMP-9 and EMT-protective molecule E-cadherin in YES-2 and TE13 cells treated with DAC.	21303982 28152502
Growth inhibition assay	Cell viability; PubMed: 26384351 Oncotarget Cells were treated with Decitabine for 72 h. Viability was measured by MTT assay in AML cells and patient samples Different AML cells.	26384351

In vivo

In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse DNA synthesis assay : The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [³H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:^[1]	- Collapse Cell lines: HL-60 and KG1a Concentrations: 0-500 nM Incubation Time: 96 hours Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines. (Only for Reference)
Animal Research:^[2]	- Collapse Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice. Dosages: ≤2.5 mg/kg Administration: Administered via i.p. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	45 mg/mL (197.18 mM)
	Water	10 mg/mL (43.81 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): water For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Decitabine SDF

Molecular Weight	228.21
Formula	C₈H₁₂N₄O₄
CAS No.	2353-33-5
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine
Smiles	NC1=NC(=O)N(C=N1)C2CC(O)C(CO)O2

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04086238	Completed	Drug: Decitabine	Healthy	EpiDestiny Inc.	October 8 2019	Phase 1
NCT04113616	Recruiting	Drug: KRT-232\|Drug: Cytarabine\|Drug: Decitabine	Acute Myeloid Leukemia (AML)\|Acute Myeloid Leukemia (AML) Secondary to Myeloproliferative Neoplasms (MPN)	Kartos Therapeutics Inc.	September 25 2019	Phase 1\|Phase 2
NCT03828084	Completed	Drug: Decitabine	Healthy	EpiDestiny Inc.	April 3 2019	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Is S1200 a racemic mixture or a monomer?
Answer:
S1200 is R form

Choose Your Country or Region

By Signaling Pathways

By product type

Decitabine